眼睛和眼周状细胞癌:免疫检查点抑制剂的作用
1Oncologic Ophthalmic Plastic & Orbital Surgery, PLLC, Houston, Texas.
International ophthalmology clinics
|September 25, 2025
概括
免疫检查点抑制剂 (ICI),特别是PD-1抑制剂,在治疗带有轨道入侵或周围神经扩散 (PNS) 的周期性状细胞癌 (SCC) 中提供了显著的进步. 这些疗法可以缩小瘤,潜在地避免彻底的手术并保持视力.
科学领域:
- 在瘤学瘤学.
- 眼科医生 眼科 眼科
- 免疫治疗是一种免疫疗法.
背景情况:
- 带有轨道入侵或周围神经扩散 (PNS) 的周围状细胞癌 (SCC) presents显著的治疗挑战.
- 传统的治疗方法,如手术和辐射,可能会导致形和视力丧失.
研究的目的:
- 评估免疫检查点抑制剂 (ICI),特别是PD-1 抑制剂在治疗晚期周期性SCC时的疗效.
- 评估ICI在减少急性手术干预的需要和减轻辐射诱导的眼睛毒性方面的潜力.
主要方法:
- 这项研究侧重于用PD-1抑制剂治疗周期性SCC患者的临床结果.
- 分析瘤反应,避免手术,维护视力和眼功能.
主要成果:
- 在局部发达的周期性SCC中,ICI显示出显著的瘤缩与轨道入侵,可能避免轨道外.
- PD-1 抑制剂被证明对带有 PNS 的 SCC 有效,作为高剂量轨道辐射的替代品,从而防止视力丧失和眼睛毒性.
- 在结合性SCC病例中观察到瘤缩,在PD-1抑制剂治疗后瘤突变负担很高.
结论:
- PD-1 抑制剂代表了先进的周期性SCC的主要治疗进展,提供器官保存和改善功能结果.
- ICI为周期性SCC提供了有价值的治疗选择,特别是在涉及轨道入侵,PNS或高瘤突变负担的病例中,改善了患者的预后和生活质量.
关键词:
这是一个OSSNN.在Cemiplimab,我们可以看到.结膜状细胞癌的结膜状细胞癌.眼睛 眼睛 眼睛 眼睛 眼睛免疫检查点抑制剂 免疫检查点抑制剂这就是尼沃卢马布 (nivolumab).轨道 轨道 轨道 轨道这就是Pembrolizumab.这是一个古老的古老时期.状细胞癌 (SCLC) 是一种状细胞癌.更多相关视频
相关概念视频
Tumor Immunotherapy
1.8K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
1.8K
Open Angle Glaucoma: Treatment
963
In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
Drugs such as carbonic anhydrase inhibitors, α2- and...
963


